Impact of Baseline Clinicopathologic and Genomic Features on Outcomes to KRAS G12C Inhibitors in Patients with NSCLC

被引：0
|
作者：
Lamberti, G. [1 ]
Ricciuti, B. [1 ]
Alessi, J. V. [1 ]
Barrichello, A. P. C. [1 ]
Pecci, F. [1 ]
Vaz, V. R. [1 ]
Sholl, L. M. [2 ]
Awad, M. M. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
KRAS G12C; KRAS inhibitors; Predictive factors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.09
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [41] Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
    Qunaj, Lindor
    May, Michael S.
    Neugut, Alfred I.
    Herzberg, Benjamin O.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] Use of sotorasib in KRAS p. G12C mutated NSCLC: a case report
    Barot, Hasti
    Evans, Joanne
    Mohammed, Waleed
    Power, Danielle
    LUNG CANCER, 2022, 165 : S77 - S77
  • [43] KRAS G12C mutation is not undruggable anymore
    Rodrigues, Manuel
    BULLETIN DU CANCER, 2020, 107 (02) : 145 - 145
  • [44] Discovery of potent CNS-penetrant covalent KRAS G12C inhibitors
    Bae, Jae Hyun
    Lew, Erin D.
    Feng, Jun
    Gonzalez-Lopez, Marcos
    Oh, Joanne
    Fagan, Patrick
    Salie, Matt
    Isley, Nick
    Lam, Richard
    Irimia, Adriana
    Nevarez, Robin
    Lin, Bingzhen
    Congdon, Taylor
    Zhang, Jingchuan
    Xuan, Dawei
    Chen, Ping
    Vernier, Jean-Michel
    Shoemaker, Robert
    CANCER RESEARCH, 2022, 82 (12)
  • [45] Concurrent inhibition of KRAS G12C and ERK1/2 overcomes acquired resistance to KRAS G12C inhibitors (G12Cis) conferred by various genetic alterations
    Wang, W.
    Lim, S. M.
    Yu, M. R.
    Cho, B. C.
    Chen, C.
    Wu, W.
    Zhang, J.
    Chen, Z. J.
    Wu, Y. L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S118 - S118
  • [46] KRAS G12C inhibitors in metastatic colorectal cancer: a tale of two targets
    Martinez-Perez, Julia
    Valladares-Ayerbes, Manuel
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 9
  • [47] Farnesyltransferase inhibitors show synergistic anticancer effects in combination with novel KRAS G12C inhibitors
    Timar, Jozsef
    Baranyi, Marcell
    Molnar, Eszter
    Randelovic, Ivan
    Cserepes, Mihaly
    Tovari, Jozsef
    Hegedus, Balazs
    CANCER RESEARCH, 2024, 84 (07)
  • [48] Establishment of KRAS G12C mutant brain metastasis models for preclinical evaluation of KRAS G12C targeted anticancer therapy
    Chen, Qikuan
    Wang, Guilan
    Yin, Yingfei
    CANCER RESEARCH, 2024, 84 (06)
  • [49] KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors through mTOR signaling inhibition
    Patel, H.
    Chan, S.
    Smith, A.
    Burrows, F.
    Malik, S.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S146 - S146
  • [50] Real-world treatment pattern and clinical outcome in Chinese NSCLC patients with KRAS G12C mutation
    Shen, L.
    Song, Z.
    Yin, Y.
    Lei, Y.
    Lu, S.
    ANNALS OF ONCOLOGY, 2024, 35
12345